BMS and Century Therapeutics are working together as part of a research cooperation and licence agreement to manufacture and market allogeneic cell therapies produced from iPSCs.
Century Therapeutics will benefit from an initial figure of $100 million with BMS putting an additional $50 million in their stock. It is possible Century may also receive an additional $3 billion in milestone payments and royalties.
“BMS and Century Therapeutics are working together as part of a research cooperation and licence agreement to manufacture and market allogeneic cell therapies produced from iPSCs“
Century will be in charge of finding suitable candidates as well as preclinical development. BMS will be in charge of marketing and clinical development.
Century Therapeutic's CEO, Lalo Flores, looks at the collaboration as a way to “further expand our pipeline of iPSC-derived cell therapy products” and “increase the probability of technical success of these programs.” He continued: “this will enable deployment of our next-generation iPSC platform to develop products targeting malignancies that are difficult for biotech companies to tackle on their own.”
Lead researcher at BMS, Rupert Vessey, expressed that this is “an important part of our investment strategy in next-generation cell therapies for haematologic and solid tumours.”
© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.See all the latest jobs in Pharmaceutical